Latest News

EXACT SCIENCES ANNOUNCES FDA ADVISORY COMMITTEE UNANIMOUSLY RECOMMENDS APPROVAL OF COLOGUARD

March 27, 2014 / by Exact Sciences
MADISON, Wis. -- Exact Sciences Corp. (Nasdaq: EXAS) today announced that the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee determined by a unanimous vote of 10 to zero that Exact Sciences has demonstrated safety, effectiveness and a favorable risk benefit profile of Cologuard®, the company's stool-based DNA (sDNA), non-invasive colorectal cancer screening test. Read full post »

Exact Sciences’ DeeP-C Study Results Published in New England Journal of Medicine

March 19, 2014 / by Exact Sciences
MADISON, Wis., March 19, 2014 – Exact Sciences Corp. (Nasdaq: EXAS) today announced that results from its DeeP-C pivotal clinical study have been published online in the “New England Journal of Medicine”. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3, 2014 print issue. Read full post »

DeeP-C Clinical Trial Preliminary Top-Line Results

April 18, 2013 / by Exact Sciences
Exact Sciences Corp. (Nasdaq: EXAS) today announced that preliminary analysis shows that the company’s Cologuard colorectal cancer screening test met or exceeded all primary and secondary endpoints of its recently completed DeeP-C pivotal clinical trial. Read full post »

Exact Sciences Receives AMGA Distinguished Corporate Partner Award

March 15, 2013 / by Exact Sciences
ORLANDO, FL., Mar. 15 – The American Medical Group Association (AMGA) announced today that it will present the AMGA Distinguished Corporate Partner Award on March 15 to Exact Sciences at its 2013 Annual Conference, March 14-16 at the Hilton Bonnet Creek Resort in Orlando. Read full post »

Exact Sciences completes enrollment of deep-c clinical trial for colorectal cancer screening

November 15, 2012 / by Exact Sciences
MADISON, Wis., Nov. 15 – Exact Sciences Corp. (Nasdaq: EXAS) today announced it has completed patient enrollment in its DeeP-C pivotal trial for colorectal cancer screening. The study enrolled more than 12,700 patients at sites in the United States and Canada. Read full post »

New Noninvasive Test for Colorectal Cancer Shows Promise

October 16, 2012 / by Exact Sciences
ANAHEIM, Calif., Oct. 16, 2012 -- A new noninvasive test for colorectal cancer screening demonstrated high sensitivity for detecting colorectal cancer, in particular precancers that are most likely to develop into cancer, according to data presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held here Oct. 16-19, 2012. Read full post »